TY - JOUR AU - Bukhari, M. PY - 2012 DA - 2012// TI - Drug-induced rheumatic diseases: a review of published case reports from the last two years JO - Curr Opin Rheumatol VL - 24 UR - https://doi.org/10.1097/BOR.0b013e32835059cd DO - 10.1097/BOR.0b013e32835059cd ID - Bukhari2012 ER - TY - JOUR AU - Johnson, D. B. AU - Balko, J. M. AU - Compton, M. L. AU - Chalkias, S. AU - Gorham, J. AU - Xu, Y. PY - 2016 DA - 2016// TI - Fulminant Myocarditis with Combination Immune Checkpoint Blockade JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1609214 DO - 10.1056/NEJMoa1609214 ID - Johnson2016 ER - TY - JOUR AU - Iwai, Y. AU - Ishida, M. AU - Tanaka, Y. AU - Okazaki, T. AU - Honjo, T. AU - Minato, N. PY - 2002 DA - 2002// TI - Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade JO - Proc Natl Acad Sci U S A. VL - 99 UR - https://doi.org/10.1073/pnas.192461099 DO - 10.1073/pnas.192461099 ID - Iwai2002 ER - TY - JOUR AU - Rui, Y. AU - Honjo, T. AU - Chikuma, S. PY - 2013 DA - 2013// TI - Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response JO - Proc Natl Acad Sci U S A VL - 110 UR - https://doi.org/10.1073/pnas.1315828110 DO - 10.1073/pnas.1315828110 ID - Rui2013 ER - TY - JOUR AU - Weber, J. S. AU - Postow, M. AU - Lao, C. D. AU - Schadendorf, D. PY - 2016 DA - 2016// TI - Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents JO - Oncologist VL - 21 UR - https://doi.org/10.1634/theoncologist.2016-0055 DO - 10.1634/theoncologist.2016-0055 ID - Weber2016 ER - TY - JOUR AU - Garcia-Cruz, A. AU - Garcia-Doval, I. PY - 2010 DA - 2010// TI - Images in clinical medicine. Gottron's papules and dermatomyositis JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMicm1002816 DO - 10.1056/NEJMicm1002816 ID - Garcia-Cruz2010 ER - TY - JOUR AU - Joshi, D. AU - Mahmood, R. AU - Williams, P. AU - Kitchen, P. PY - 2008 DA - 2008// TI - Dysphagia secondary to dermatomyositis treated successfully with intravenous immunoglobulin: a case report JO - Int Arch Med VL - 1 UR - https://doi.org/10.1186/1755-7682-1-12 DO - 10.1186/1755-7682-1-12 ID - Joshi2008 ER - TY - JOUR AU - Dimachkie, M. M. AU - Barohn, R. J. PY - 2012 DA - 2012// TI - Idiopathic inflammatory myopathies JO - Semin Neurol VL - 32 UR - https://doi.org/10.1055/s-0032-1329201 DO - 10.1055/s-0032-1329201 ID - Dimachkie2012 ER - TY - JOUR AU - Ofori, E. AU - Ramai, D. AU - Ona, M. AU - Reddy, M. PY - 2017 DA - 2017// TI - Paraneoplastic Dermatomyositis Syndrome Presenting as Dysphagia JO - Gastroenterology Res VL - 10 UR - https://doi.org/10.14740/gr841w DO - 10.14740/gr841w ID - Ofori2017 ER - TY - JOUR AU - Thiers, B. H. AU - Sahn, R. E. AU - Callen, J. P. PY - 2009 DA - 2009// TI - Cutaneous manifestations of internal malignancy JO - CA Cancer J Clin VL - 59 UR - https://doi.org/10.3322/caac.20005 DO - 10.3322/caac.20005 ID - Thiers2009 ER - TY - JOUR AU - Sigurgeirsson, B. AU - Lindelöf, B. AU - Edhag, O. AU - Allander, E. PY - 1992 DA - 1992// TI - Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study JO - N Engl J Med VL - 326 UR - https://doi.org/10.1056/NEJM199202063260602 DO - 10.1056/NEJM199202063260602 ID - Sigurgeirsson1992 ER - TY - JOUR AU - Chen, Y. J. AU - Wu, C. Y. AU - Huang, Y. L. AU - Wang, C. B. AU - Shen, J. L. AU - Chang, Y. T. PY - 2010 DA - 2010// TI - Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan JO - Arthritis Res Ther VL - 12 UR - https://doi.org/10.1186/ar2987 DO - 10.1186/ar2987 ID - Chen2010 ER - TY - JOUR AU - Fiorentino, D. F. AU - Chung, L. S. AU - Christopher-Stine, L. AU - Zaba, L. AU - Li, S. AU - Mammen, A. L. PY - 2013 DA - 2013// TI - Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ JO - Arthritis Rheum VL - 65 UR - https://doi.org/10.1002/art.38093 DO - 10.1002/art.38093 ID - Fiorentino2013 ER - TY - JOUR AU - Kang, Y. K. AU - Boku, N. AU - Satoh, T. AU - Ryu, M. H. AU - Chao, Y. AU - Kato, K. PY - 2017 DA - 2017// TI - Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)31827-5 DO - 10.1016/S0140-6736(17)31827-5 ID - Kang2017 ER - TY - JOUR AU - Abdel-Wahab, N. AU - Shah, M. AU - Suarez-Almazor, M. E. PY - 2016 DA - 2016// TI - Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0160221 DO - 10.1371/journal.pone.0160221 ID - Abdel-Wahab2016 ER - TY - JOUR AU - Baxi, S. AU - Yang, A. AU - Gennarelli, R. L. AU - Khan, N. AU - Wang, Z. AU - Boyce, L. PY - 2018 DA - 2018// TI - Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis JO - BMJ VL - 360 UR - https://doi.org/10.1136/bmj.k793 DO - 10.1136/bmj.k793 ID - Baxi2018 ER - TY - JOUR AU - Kudo, F. u. m. i. a. k. i. AU - Watanabe, Y. a. s. u. t. a. k. a. AU - Iwai, Y. u. k. i. AU - Miwa, C. h. i. h. i. r. o. AU - Nagai, Y. o. s. h. i. a. k. i. AU - Ota, H. i. r. o. m. i. t. s. u. AU - Yabe, H. i. r. o. k. i. AU - Demitsu, T. o. s. h. i. o. AU - Hagiwara, K. o. i. c. h. i. AU - Koyama, N. o. b. u. y. u. k. i. AU - Koyama, S. h. i. n. i. c. h. i. r. o. PY - 2018 DA - 2018// TI - Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis JO - Internal Medicine VL - 57 UR - https://doi.org/10.2169/internalmedicine.9381-17 DO - 10.2169/internalmedicine.9381-17 ID - Kudo2018 ER -